Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Classifica tra le azioni
#3422
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Prezzo delle azioni
$4.48
Capitalizzazione di mercato
$4.99B
Variazione (1 giorno)
-5.20%
Variazione (1 anno)
-41.89%
Paese
CN
Scambia Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Categoria
Healthcare
Utile per Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Utile nel Jun 2026 TTM: $95.41M
Secondo gli ultimi rapporti finanziari di Shenzhen Salubris Pharmaceuticals Co., Ltd., gli utili attuali della società sono $95.41M. Nel 2024, la società ha registrato un utile di $86.66M, una diminuzione rispetto a agli utili del 2023, che erano di $90.66M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Shenzhen Salubris Pharmaceuticals Co., Ltd. dal 2006 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $95.41M | 1.77% |
| 2025 | $93.75M | 8.18% |
| 2024 | $86.66M | -4.42% |
| 2023 | $90.66M | -12.38% |
| 2022 | $103.47M | 9.64% |
| 2021 | $94.38M | 986.53% |
| 2020 | $8.69M | -92.90% |
| 2019 | $122.26M | -50.71% |
| 2018 | $248.05M | -5.91% |
| 2017 | $263.64M | 10.90% |
| 2016 | $237.72M | 3.50% |
| 2015 | $229.68M | 16.86% |
| 2014 | $196.54M | 22.09% |
| 2013 | $160.97M | 33.79% |
| 2012 | $120.32M | 59.83% |
| 2011 | $75.28M | 19.59% |
| 2010 | $62.95M | 72.35% |
| 2009 | $36.52M | 96.81% |
| 2008 | $18.56M | 76.92% |
| 2007 | $10.49M | 123.31% |
| 2006 | $4.70M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $3.62B | 3,693.17% |
US
|
|
| $4.11B | 4,206.59% |
FR
|
|
| $2.19B | 2,197.71% |
JP
|
|
| $1.59B | 1,566.52% |
US
|
|
| $738.72M | 674.27% |
CH
|
